Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases. The Company has developed a robust portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning. Renibus’ first-in-class lead program, RBT-1 (SnPP / FeS), is a potent inducer of Nrf2, IL-10, and ferritin. RBT-1 is currently in Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. RBT-2 (tetrahydrocurmin) is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models and will be in IND enabling and clinical development in 2023. RBT-3 (FeS), a novel, low molecular weight iron nanoparticle, is one component of RBT-1 and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be in clinical development in 2023. RBT-9 (SnPP), a potent anti-inflammatory and antioxidant drug with anti-viral properties, is one component of RBT-1. It has been investigated in a 42-patient Phase 2 RCT in COVID pneumonia as a monotherapy in hospitalized patients. RBT-9 reduced hospital length of stay by ~70%. Additional pre-clinical work is underway in NASH progression to help inform the clinical development strategy.
View Top Employees from Renibus Therapeutics IncWebsite | http://renibus.com |
Employees | 36 (30 on RocketReach) |
Founded | 2016 |
Address | 181 Grand Ave 225, Southlake, Texas 76092, US |
Phone | (682) 285-1711 |
Technologies |
JavaScript,
HTML,
PHP
+13 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Other Healthcare Services, Pharmaceuticals, Drug Discovery, Healthcare |
Competitors | AQUALUNG THERAPEUTICS CORPORATION, Boehringer Ingelheim Venture Fund, CohBar, Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Renibus Therapeutics Inc employee's phone or email?
Bhupinder Singh is the Chief Medical Officer of Renibus Therapeutics Inc.
30 people are employed at Renibus Therapeutics Inc.
Renibus Therapeutics Inc is based in Southlake, Texas.
The NAICS codes for Renibus Therapeutics Inc are [325, 32].
The SIC codes for Renibus Therapeutics Inc are [873, 87].